13F Pro13F Pro

Sofinnova Ventures Inc

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1631134
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare100.0%$1.9B

AUM History

13fpro.ai/research/fund/sofinnova-ventures-inc-1631134

Conviction and streaks

Concentrating · top 10 = 59.8%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

NTRA$NTRAConviction hold22.5% weight · held 10 quartersVERA$VERAConviction hold6.4% weight · held 10 quartersJAZZ$JAZZConviction hold4.7% weight · held 8 quartersRAPP$RAPPConviction hold4.2% weight · held 9 quartersAVBP$AVBPConviction hold3.1% weight · held 10 quartersPHVS$PHVSAccumulating+51% shares · 4 quarters runningSUPN$SUPNAccumulating+175% shares · 3 quarters runningIMTX$IMTXAccumulating+65% shares · 3 quarters runningIMNM$IMNMAccumulating+295% shares · 3 quarters runningEWTX$EWTXTrimming-47% shares · 4 quarters runningPRAX$PRAXTrimming-96% shares · 3 quarters runningJAZZ$JAZZTrimming-62% shares · 2 quarters runningINBX$INBXTrimming-33% shares · 2 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/sofinnova-ventures-inc-1631134

Sofinnova Ventures Inc 13F holdings — Q2 2026

$1.9B portfolio (-26.5% QoQ) · 57 holdings · Q2 2026 13F · top 10 are 60% of the stock portfolio

Includes $62.2M of put/call options ($13.8M puts, $48.4M calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $1.9B. Weights use the stock portfolio.

All holdings — Sofinnova Ventures Inc (Q2 2026)

57 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
SUPN$SUPNSUPERNUS PHARMACEUTICALS, INC.$48.2M+9%
RYTM$RYTMRHYTHM PHARMACEUTICALS, INC.$45.3M-9%
GILD$GILDGILEAD SCIENCES, INC.$43.3MNew
UTHR$UTHRUNITED THERAPEUTICS Corp$41.4M-52%
COGT$COGTCogent Biosciences, Inc.$40.1M-51%
AXSM$AXSMAxsome Therapeutics, Inc.$39.3M-25%
IMTX$IMTXImmatics N.V.$37.2M+1%
DYN$DYNDyne Therapeutics, Inc.$36.8M+1%
IMNM$IMNMImmunome Inc.$36.5M+1%
IDYA$IDYAIDEAYA Biosciences, Inc.$34.5M-18%
ANAB$ANABANAPTYSBIO, INC$33.3M+99%
NKTR$NKTRNEKTAR THERAPEUTICS$32.9M-7%
PHVS$PHVSPharvaris N.V.$30.5M+8%
RCUS$RCUSArcus Biosciences, Inc.$29.2M+2%
INBX$INBXInhibrx Biosciences, Inc.$28.7M-25%

What changed in Q2 2026

Against the previous quarter's 13F: 13 new, 14 added to, 17 trimmed, 30 sold out. Share-count changes; largest moves by dollar size first.

New positions (13)

  • SPTX$SPTXSeaport Therapeutics, Inc.$77.4M

    first bought this quarter

  • GILD$GILDGILEAD SCIENCES, INC.$43.3M

    first bought this quarter

  • ISRG$ISRGCALLINTUITIVE SURGICAL INC$15.9M

    first bought this quarter

  • GMED$GMEDCALLGLOBUS MEDICAL INC$15.8M

    first bought this quarter

  • NRIX$NRIXNurix Therapeutics, Inc.$12.7M

    first bought this quarter

  • DSGN$DSGNDesign Therapeutics, Inc.$12.5M

    first bought this quarter

+7 more in the Excel export

Added to (14)

  • GMAB$GMABGENMAB A/S+438%

    now $111.1M · held 2 qtrs, 2 adds in a row

  • ANAB$ANABANAPTYSBIO, INC+99%

    now $33.3M · held 7 qtrs

  • MANE$MANEVeradermics, Inc+103%

    now $18.3M · held 2 qtrs, 2 adds in a row

  • TENX$TENXTENAX THERAPEUTICS, INC.+379%

    now $7.3M · held 2 qtrs, 2 adds in a row

  • RARE$RARECALLUltragenyx Pharmaceutical Inc.+43%

    now $16.7M

  • IRON$IRONDisc Medicine, Inc.+87%

    now $10.7M · held 10+ qtrs

+8 more in the Excel export

Trimmed (17)

  • BMY$BMYBRISTOL MYERS SQUIBB CO-56%

    now $50.5M · held 3 qtrs

  • JAZZ$JAZZJazz Pharmaceuticals plc-39%

    now $88.0M · held 8 qtrs, 2 trims in a row

  • RARE$RAREUltragenyx Pharmaceutical Inc.-45%

    now $57.3M · held 3 qtrs

  • UTHR$UTHRUNITED THERAPEUTICS Corp-52%

    now $41.4M · held 5 qtrs

  • COGT$COGTCogent Biosciences, Inc.-51%

    now $40.1M · held 10+ qtrs

  • ALC$ALCALCON INC-65%

    now $17.2M · held 3 qtrs

+11 more in the Excel export

Sold out (30)

  • PUTiShares TRwas $148.8M
  • PUTSPDR Series Trustwas $134.1M
  • AZN$AZNASTRAZENECA PLCwas $89.9M

    held 1 qtr

  • QQQ$QQQPUTINVESCO QQQ TRUST, SERIES 1was $86.6M
  • PUTiShares TRwas $80.2M
  • UTHR$UTHRPUTUNITED THERAPEUTICS Corpwas $47.6M

+24 more in the Excel export

Share

Holdings by quarter

Every 13F Sofinnova Ventures Inc has filed, 33 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Sofinnova Ventures?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Sofinnova Ventures's top 20 holdings: 49/100 (our AI quality score, weighted by position size; 12 of the 20 are scored)

Top 10 since filing

+1.5%

Value-weighted move of the 10 largest stock positions

Turnover

16%

Last quarter; 84% over the last 4

Top 10 weight

60%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

74%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Sofinnova Ventures Inc disclosed 57 positions worth $1.9B in its Form 13F-HR for Q2 2026 — $1.9B in common stock plus $62.2M of put/call option positions (reported at underlying notional value, not premium at risk), led by $NTRA (Natera, Inc.) at 22.5% of the equity portfolio, followed by $VERA and $GMAB. During the quarter the fund opened 13 new positions and exited 30 — including a new stake in $SPTX. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Sofinnova Ventures Inc’s Form 13F-HR filing with the SEC under CIK 1631134.

Funds like this

managers whose biggest positions overlap Sofinnova Ventures's
Duquesne Family Office LLC$5.21B 13F book · 3 shared top holdingsNTRAINSMRYTMDeep Track Capital, LP$6.87B 13F book · 9 shared top holdingsGMABVERAAXSMCOGTVestal Point Capital, LP$4.28B 13F book · 13 shared top holdingsUTHRDYNNKTRIMTXDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)$9.59B 13F book · 7 shared top holdingsGMABUTHRCOGTVERANWI MANAGEMENT LP$2.16B 13F book · 3 shared top holdingsNTRAINSMCOGTLogos Global Management LP$2.32B 13F book · 9 shared top holdingsVERADYNIDYACOGT

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Sofinnova Ventures Inc

13F Pro is an AI hedge fund tracker and stock research platform. For Sofinnova Ventures Inc (SEC CIK: 1631134), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Sofinnova Ventures Inc's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.